Chicago, Illinois — This week the American Transportation Research Institute (ATRI) announced a new survey aimed at uncovering how legalized cannabis is reshaping driver recruitment, retention, and drug‑testing practices across the nation.

With 38 states now permitting medical cannabis, 21 allowing recreational use, and seven authorizing low‑THC CBD products, the legal landscape for marijuana has expanded dramatically. Yet the federal Department of Transportation keeps marijuana classified as a Schedule I drug, and the FMCSA’s Drug and Alcohol Testing Regulation (49 CFR Part 40) explicitly bars its use in any capacity for commercial drivers. That regulatory stance clashes with a rising trend of marijuana‑positive drug tests among truckers, prompting industry stakeholders to ask whether legalization will erode the safety net that has long protected highways.

ATRI’s 2019 study already linked the surge in recreational cannabis to a 32% jump in positive tests—41,000 drivers in 2023 compared to 31,000 the previous year—yet the agency could not disclose testing volumes. In 2022, ATRI’s Research Advisory Committee flagged research on the effects of legalized cannabis as a top priority, and the new survey will gather insights from carriers on hiring policies for drivers with past positive tests, current drug‑testing protocols, labor‑pool trends, and strategies for dealing with legal marijuana use. The online questionnaire will remain open until March 17, with a driver‑specific survey launching in two weeks. An analysis of both polls is slated for mid‑year, offering fresh data on the industry’s evolving challenges.

What This Means for Drivers

For CDL‑A holders, the study reinforces that a positive marijuana test remains disqualifying, regardless of state law. Owner‑operators must stay vigilant, as fleet managers often rely on third‑party testing and must navigate the tension between state‑level legalization and federal prohibition. OTR truck drivers, who frequently travel across state lines, face the same regulatory uniformity, meaning a single positive result can jeopardize a multi‑state route. The findings will likely prompt carriers to clarify policies, ensuring drivers understand that recreational use is still prohibited under FMCSA regulations.

Industry Reaction

While ATRI’s initiative has been welcomed by some carrier associations, many fleet managers express concern that the lack of clear federal guidance could lead to inconsistent hiring practices. FaLisa McCannon, supervisor at OOIDA’s Consortium Management Co., Inc., emphasized that “if you hold a CDL and you’re driving a DOT truck anywhere in the United States, it’s still not acceptable to partake in marijuana, regardless of what your state has in place.” Industry groups are calling for a unified approach that balances driver rights with safety imperatives, especially as more carriers seek to attract a younger workforce amid the rising popularity of cannabis.

Key Points

• ATRI’s new survey targets driver recruitment, retention, and drug‑testing practices amid shifting marijuana laws.
• Federal FMCSA regulations prohibit marijuana use for all commercial drivers, regardless of state legalization.
• The 2019 ATRI study reported a 32% increase in marijuana‑positive drug tests, totaling 41,000 drivers in 2023.
• Survey results expected mid‑year could guide carriers on policy adjustments and safety protocols.

Looking for a better trucking job? US Trucker's free job‑matching service connects CDL‑A drivers, OTR drivers, regional drivers, and owner‑operators with 500+ top US carriers. Leave your details in the form on this page and a recruiter will call you within one business day. Trucking companies are hiring now.

Photo by Alexander gomez on Pexels